Shor Oded, Rabinowitz Roy, Offen Daniel, Benninger Felix
Department of Neurology, Rabin Medical Center, Petach Tikva 4941492, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Comput Struct Biotechnol J. 2022 Apr 20;20:2013-2019. doi: 10.1016/j.csbj.2022.04.026. eCollection 2022.
The CRISPR-Cas system has transformed the field of gene-editing and created opportunities for novel genome engineering therapeutics. The field has significantly progressed, and recently, CRISPR-Cas9 was utilized in clinical trials to target disease-causing mutations. Existing tools aim to predict the on-target efficacy and potential genome-wide off-targets by scoring a particular gRNA according to an array of gRNA design principles or machine learning algorithms based on empirical results of large numbers of gRNAs. However, such tools are unable to predict the editing outcome by variant Cas enzymes and can only assess potential off-targets related to reference genomes. Here, we employ normal mode analysis (NMA) to investigate the structure of the Cas9 protein complexed with its gRNA and target DNA and explore the function of the protein. Our results demonstrate the feasibility and validity of NMA to predict the activity and specificity of SpyCas9 in the presence of mismatches by comparison to empirical data. Furthermore, despite the absence of their exact structures, this method accurately predicts the enzymatic activity of known high-fidelity engineered Cas9 variants.
CRISPR-Cas系统改变了基因编辑领域,并为新型基因组工程疗法创造了机会。该领域取得了显著进展,最近,CRISPR-Cas9被用于临床试验以靶向致病突变。现有的工具旨在通过根据一系列gRNA设计原则或基于大量gRNA的实验结果的机器学习算法对特定gRNA进行评分,来预测靶向效率和潜在的全基因组脱靶效应。然而,此类工具无法预测不同Cas酶的编辑结果,且只能评估与参考基因组相关的潜在脱靶效应。在此,我们采用正常模式分析(NMA)来研究与gRNA和靶DNA复合的Cas9蛋白的结构,并探索该蛋白的功能。我们的结果通过与实验数据比较,证明了NMA在存在错配情况下预测SpyCas9活性和特异性的可行性和有效性。此外,尽管未知其精确结构,但该方法准确预测了已知高保真工程Cas9变体的酶活性。